CDKN2A and breast cancer: Other genomic mutations have been investigated in plasma ct-DNA of patients with BC treated with CDK4/6 inhibitors, such as PIK3CA, TP53, MYC, CCND1, CDK4, CDKN1, CDKN2, NF1, and ERBB2 [45,49].